CME Part I: Immune checkpoint inhibitors to treat cutaneous malignancies

This article reviews the indications, efficacy, safety profile and evidence supporting checkpoint inhibition as therapeutics for metastatic melanoma, cutaneous squamous cell carcinoma, and Merkel cell carcinoma.

Source: Journal of the American Academy of Dermatology - May 22, 2020 Category: Dermatology Authors: Dulce M. Barrios, Mytrang H. Do, Gregory S. Phillips, Michael A. Postow, Tomoko Akaike, Paul Nghiem, Mario E. Lacouture Source Type: research